Sulphasalazine induced hepatitis in juvenile rheumatoid arthritis.

Sulphasalazine induced hepatitis in juvenile rheumatoid arthritis.

Two 19 year old patients with juvenile chronic arthritis developed liver toxicity during treatment with sulphasalazine. A significant increase in the levels of liver enzymes in serum samples was noticed in relation to the initiation of treatment in one patient and to the increase in dose in the second. The enzymes returned to normal levels 14 days after the drug had been stopped. A rechallenge ...

Sulphasalazine treatment in rheumatoid arthritis.

Sulphasalazine induced selective IgA deficiency in rheumatoid arthritis.

and the mean observed peak plasma metoprolol concentration by about 33%. Furthermore, the elimination half life of metoprolol was prolonged from 3-9 hours during monotreatment to 6-0 hours when ranitidine was given in combination (p<0005). There was no evidence that any of the volunteers were poor metabolisers of metoprolol. Beta-blockade was assessed on the sixth treatment day by examining the...

Anticardiolipin Antibodies in Juvenile Rheumatoid Arthritis and Systemic Lupus Erythematosus

Background: Antiphospholipid antibody syndrome (APS) can either occur as a primary syndrome or associated with other autoimmune diseases such as systemic lupus erythematosus (SLE). Anticardiolipin antibody (aCL) of IgG and/or IgM isotype in blood, measured by a standardized ELISA is the most acceptable laboratory criteria. APS IgG isotype, particularly IgG2 subclass is more strongly associated ...

Leucopenia during sulphasalazine treatment for rheumatoid arthritis.

Leucopenia appears to be a more frequent complication of sulphasalazine treatment in rheumatoid arthritis than in inflammatory bowel disease and poses a management problem. In this study leucopenia was found in 20 patients, 14 of whom were participating in prospective studies (252 patients), giving an incidence of 5.6%. Treatment had to be discontinued in half of these patients. Most (14) episo...